Skip to main content
Xuanzhu Biopharmaceutical Co., Ltd. logo

Xuanzhu Biopharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 2575 ISIN · CNE1000074Q1 HKEX Manufacturing
Open in API
Filings indexed 55 across all filing types
Latest filing 2026-05-27 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 2575

About Xuanzhu Biopharmaceutical Co., Ltd.

http://www.xuanzhubio.com

Xuanzhu Biopharmaceutical Co., Ltd. is an innovative drug research and development (R&D) enterprise specializing in the development, manufacturing, and commercialization of both small-molecule chemical drugs and macromolecular drugs. The company focuses on therapeutic areas including digestive diseases, oncology, and NASH (Non-alcoholic steatohepatitis), maintaining a pipeline of over ten drug assets in active development. Key commercialized products include the Class 1 innovative drug, Anaprozole sodium enteric-coated tablets. The company is also developing advanced oncology treatments, such as the Bireociclib regimen for advanced breast cancer, demonstrating a commitment to proprietary, innovative medicines.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form of Proxy for an upcoming Annual General Meeting, providing shareholders the means to appoint proxies and vote on specific resolutions. This is part of the proxy solicitation package sent to shareholders to request voting instructions, rather than the AGM materials themselves or the results. Therefore, it fits the definition of Proxy Solicitation & Information Statement (PSI).
2026-05-27 English
NOTICE OF THE 2025 ANNUAL GENERAL MEETING
AGM Information Classification · 92% confidence The document is a Notice of the 2025 Annual General Meeting (AGM) of Xuanzhu Biopharmaceutical Co., Ltd. It includes the date, venue, agenda items (ordinary and special resolutions), record dates, proxy details, and other procedural notes for the AGM. It is clearly an AGM notice and not the meeting materials or minutes, so it fits the “AGM Information” category.
2026-05-27 English
CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING
Regulatory Filings
2026-05-27 English
PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION, ABOLITION OF THE SUPERVISORY COMMITTEE AND CHANGE OF BOARD COMPOSITION
Governance Information Classification · 85% confidence The document is an HKEX listing rule announcement detailing proposed amendments to the company’s articles of association (governance documents), the abolition of the supervisory committee, and changes to the board composition. It focuses on internal governance structure and rules rather than reporting financial results or soliciting proxy votes. Therefore it fits the Governance Information category.
2026-05-26 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 93% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Listing Rules to report changes in issued shares (conversion of unlisted shares to H shares and their listing). It is not an earnings or management report, nor a mere announcement of a report—rather it is a direct disclosure of a share capital change. This matches the 'Share Issue/Capital Change' category (SHA).
2026-05-12 English
INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY
Share Issue/Capital Change Classification · 87% confidence The document is an official announcement by the company regarding the completion of its H Share full circulation, including details of share conversion and updated share capital percentages. This is a corporate announcement about a change in share capital structure rather than a report of financial results or board appointments. Therefore, it fits the 'Share Issue/Capital Change' category (SHA).
2026-05-12 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.